This week’s vault exercise looks back to our coverage of The EASL Congress 2023, when the panel discusses the role of FIB-4 and other elements in the clinical care pathway.
Hannes Hagstrom and the Surfers consider the ways that increased access to in-office screening will affect clinical care pathways, with special focus on the role of primary care practices.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
The launch of Rezdiffra raises this pivotal question: which MASH patients are the correct initial targets for the first MASH drug?
As panelists ponder practical issues about when and to whom to prescribe Rezdiffra, they consider the benefits and shortcomings of existing NITs.
Key Opinion Leaders for Europe and the US join the Surfers the day after the first MASH drug, Rezdiffra, was approved, to discuss how they heard the news and what kinds of patients they envision as initial targets.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
This conversation includes two separate themes: the rationale and impact around the price of resmetirom, and the impact of GLP-1s on resmetirom use in patients with MASH.
This conversation looks at different strategies to improve NITs in the diagnosis and staging of patients with advanced MASH Fibrosis.
